1. Home
  2. KODK vs PRME Comparison

KODK vs PRME Comparison

Compare KODK & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

BUY

Current Price

$10.07

Market Cap

982.9M

ML Signal

BUY

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.21

Market Cap

526.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KODK
PRME
Founded
1880
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
982.9M
526.0M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
KODK
PRME
Price
$10.07
$3.21
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
★ $7.11
AVG Volume (30 Days)
623.4K
★ 3.0M
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.18
EPS
★ N/A
N/A
Revenue
★ $4,114,000,000.00
$4,632,000.00
Revenue This Year
N/A
$90.67
Revenue Next Year
N/A
$19.46
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 55.28
52 Week Low
$5.78
$2.67
52 Week High
$14.87
$6.85

Technical Indicators

Market Signals
Indicator
KODK
PRME
Relative Strength Index (RSI) 65.07 61.48
Support Level $9.29 $2.84
Resistance Level $10.19 $4.03
Average True Range (ATR) 0.28 0.25
MACD 0.05 0.04
Stochastic Oscillator 86.43 98.14

Price Performance

Historical Comparison
KODK
PRME

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: